Department of Microbiology, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
Department of Microbiology, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
Int J Infect Dis. 2022 May;118:116-118. doi: 10.1016/j.ijid.2022.02.036. Epub 2022 Feb 19.
Health care workers (HCWs), a high-risk group for contracting COVID-19 disease, are being prioritized to receive COVID-19 vaccination. A third dose messenger RNA (mRNA) vaccine, mRNA-1273 (Moderna), after 2 doses of inactivated vaccine (CoronaVac), has been used to increase the level of protection against SARS-CoV-2 among Indonesian HCWs. However, data regarding antibody response after mRNA-1273 booster dose are limited.
To evaluate the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein (anti-S) titers induced by the third mRNA-1273 vaccine among fully vaccinated HCWs with CoronaVac.
A total of 90 HCWs with no history of SARS-CoV-2 infection and who had received the third dose of vaccination were included in this study. The mRNA-1273 vaccine booster was administered 6 months after completing primary vaccination with CoronaVac. After the third dose, the anti-S antibodies level significantly increased, from a median of 41.7 U/mL (interquartile range [IQR], 22.4-92.5) to 28 394 U/mL (IQR, 20 837-41 646) (p <0.0001). After the third dose, seropositivity with the anti-S antibodies level >210 U/mL was observed in all HCWs. Age was negatively associated with the anti-S antibodies level after the mRNA-1273 booster.
The heterologous prime booster with CoronaVac and mRNA-1273 vaccine booster elicit a pronounced antibody response against SARS-CoV-2 infection.
医护人员(HCWs)是感染 COVID-19 疾病的高风险人群,被优先接种 COVID-19 疫苗。在接种两剂灭活疫苗(科兴疫苗)后,第三剂信使 RNA(mRNA)疫苗 mRNA-1273(Moderna)被用于提高印度尼西亚 HCWs 对 SARS-CoV-2 的保护水平。然而,关于 mRNA-1273 加强剂量后抗体反应的数据有限。
评估第三剂 mRNA-1273 疫苗在完全接种科兴疫苗的 HCWs 中对 SARS-CoV-2 刺突(S)蛋白受体结合域(RBD)(抗-S)滴度的影响。
本研究共纳入 90 名无 SARS-CoV-2 感染史且接种过第三剂疫苗的 HCWs。mRNA-1273 疫苗加强剂在完成科兴疫苗基础免疫接种 6 个月后接种。第三剂接种后,抗-S 抗体水平显著升高,中位数从 41.7 U/mL(四分位距 [IQR],22.4-92.5)升高至 28394 U/mL(IQR,20837-41646)(p<0.0001)。第三剂接种后,所有 HCWs 的抗-S 抗体水平>210 U/mL 的血清阳性率。年龄与 mRNA-1273 加强剂后的抗-S 抗体水平呈负相关。
用科兴疫苗和 mRNA-1273 疫苗进行异源加强接种可引起针对 SARS-CoV-2 感染的明显抗体反应。